Welcome to our dedicated page for Benitec Biopharm SEC filings (Ticker: BNTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Benitec Biopharma Inc. (NASDAQ: BNTC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage, gene therapy-focused biotechnology company, Benitec uses its SEC reports to outline progress on its Silence and Replace DNA-directed RNA interference (ddRNAi) platform, the clinical development of its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia, and its financial position.
Key filings include annual reports on Form 10‑K, which summarize full-year financial results, research and development expenses related primarily to BB-301, and broader operational updates. Quarterly reports on Form 10‑Q provide interim financial statements, cash and cash equivalents balances, and management’s discussion of ongoing clinical and corporate activities. These documents allow readers to track how Benitec funds and advances its Silence and Replace-based therapeutics over time.
Benitec also files current reports on Form 8‑K to announce material events. Recent 8‑K filings have covered topics such as positive interim clinical results from the BB-301 Phase 1b/2a trial, the FDA’s Fast Track Designation for BB-301, equity financings through underwritten and registered direct offerings, and board appointments. The company’s Definitive Proxy Statement on Schedule 14A discloses information on governance, director elections, executive compensation, equity incentive plans, and the annual meeting of stockholders.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight important points from lengthy documents, such as clinical development updates, changes in cash runway, or terms of financing transactions. Users can quickly review 10‑K and 10‑Q reports with AI-generated insights, and scan Form 8‑K items for material agreements, capital raises, and regulatory news. Where applicable, Form 4 insider transaction reports can also be monitored to see how directors and officers transact in BNTC shares.
For investors analyzing Benitec’s gene therapy pipeline and financial condition, this SEC filings page offers a structured view of real-time EDGAR updates, summarized by AI, making it easier to understand the implications of complex regulatory documents without reading every line of each filing.
Benitec Biopharma Inc. (BNTC) filed an 8‑K stating it furnished a press release with financial results for the fiscal quarter ended September 30, 2025, and an operational update. The press release is attached as Exhibit 99.1.
The company notes the information furnished under Item 2.02, including Exhibit 99.1, is not deemed filed for liability purposes and is not incorporated by reference unless expressly stated. BNTC’s common stock trades on The Nasdaq Stock Market LLC.
Benitec Biopharma (BNTC) reported quarterly results with no revenue and a net loss of $8.97 million for the three months ended September 30, 2025. Operating expenses were $9.80 million, led by R&D $3.37 million and G&A $6.43 million. Cash used in operating activities was $3.35 million.
The company ended the quarter with $94.5 million in cash and cash equivalents and stated this is sufficient to fund operations for at least the next twelve months from the date of the report. Subsequent to quarter-end, Benitec completed an underwritten offering of 5,930,000 shares at $13.50 and a concurrent registered direct sale of 1,481,481 shares at $13.50, for gross proceeds of approximately $100 million. Shares outstanding were 26,250,469 as of September 30, 2025; 33,862,226 were outstanding as of November 14, 2025. Benitec continues advancing BB-301, its silence-and-replace AAV gene therapy for OPMD, with multiple subjects treated in an ongoing Phase 1b/2a study.
Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital. On 11/07/2025, the reporting persons acquired 730,370 shares of common stock at $13.5 per share and separately acquired 751,111 shares at $13.5. The holdings following these transactions were reported as 9,538,175 shares and 1,819,812 shares, respectively. The positions are listed as indirect ownership, and the filers are identified as a Director and 10% Owner. Additional explanatory notes are referenced in Exhibit 99.1.
Benitec Biopharma (BNTC) reported an insider equity award. A director received options to purchase 28,517 shares on 11/05/2025 at an exercise price of $15.78 per share. These options were granted for $0 and expire on 11/05/2035. The award will vest in full on the earlier of immediately prior to the company’s 2026 annual meeting of stockholders or November 5, 2026. Following the grant, the director holds 28,517 derivative securities directly.
Benitec Biopharma Inc. (BNTC) reported an insider ownership update. A director filed a Form 3 initial statement of beneficial ownership under Section 16. The filing states that no securities are beneficially owned.
The event date is 11/03/2025, and the form was signed by Sharon Mates on 11/07/2025. This is an administrative disclosure of initial insider status and holdings.
Benitec Biopharma Inc. (BNTC) announced two equity offerings priced at $13.50 per share. The company agreed to sell 5,930,000 shares in a firm‑commitment underwritten offering, with a 30‑day option for underwriters to buy up to 889,500 additional shares. Concurrently, it entered a registered direct sale of 1,481,481 shares to Averill funds at the same price.
Gross proceeds are expected to be approximately $100 million before fees and expenses. Underwriting and placement fees are 6.0% of gross proceeds for their respective transactions. The company, its executives and directors, and Suvretta Capital entered 90‑day lock‑ups. Closings are expected on November 7, 2025, subject to customary conditions. Proceeds are intended to support product candidate development, working capital and general corporate purposes.
Benitec Biopharma Inc. is registering and selling 7,411,481 shares of common stock at $13.50 per share. The deal combines a firm-commitment underwritten offering of 5,930,000 shares and a concurrent registered direct sale of 1,481,481 shares, both priced identically. The company has granted underwriters a 30‑day option to purchase up to 889,500 additional shares.
Gross proceeds reflect the pricing: the tables show proceeds to the company of $94,051,694 before expenses, and the company estimates net proceeds of approximately $93.6 million, or $104.9 million if the option is fully exercised. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Shares outstanding were 26,250,469 as of June 30, 2025.
Benitec plans to use the net proceeds, together with existing cash, to fund continued development of its product candidate programs, working capital, and other general corporate purposes. The underwritten public offering and the concurrent registered direct offering are contingent on each other closing. The offering price represents a discount to the last reported price of $15.78 on November 5, 2025, and new investors will incur immediate dilution described in the filing.
Benitec Biopharma Inc. (BNTC) launched a mixed primary financing, comprising an underwritten offering of common stock and pre-funded warrants, alongside a concurrent registered direct offering of common stock. The prospectus also registers the shares issuable upon exercise of the pre-funded warrants. Pre-funded warrants are immediately exercisable for one share each at a $0.0001 exercise price, with beneficial ownership limits of 4.99% (or, at the holder’s election, 9.99% or up to 19.99%).
The company’s common stock last traded at $15.71 on November 4, 2025. As of September 30, 2025, cash and cash equivalents were approximately $94.479 million. Net proceeds are intended to fund continued development of product candidates, working capital and general corporate purposes. The underwritten deal includes a 30‑day option to purchase additional shares. A concurrent registered direct offering is being made to Averill entities, affiliates of Suvretta, which beneficially own approximately 49.9% of the company.
Benitec Biopharma Inc. appointed Dr. Sharon Mates to its Board. She joins as a Class I director effective November 3, 2025, with a term through the 2026 annual meeting. The Board deemed her independent under Nasdaq rules. In connection with the appointment, she will receive stock options valued at $450,000, with the number of shares determined by dividing $450,000 by the Common Stock closing price on November 5, 2025. These options vest in full on the earlier of immediately prior to the 2026 annual meeting or the first anniversary of the grant date.
The FDA granted Fast Track Designation to BB-301 for OPMD. The company also announced a live webcast of its latest interim clinical data presentation at 8:00 a.m. Eastern on November 3, 2025. Related press releases and presentation materials were included as exhibits.
Benitec Biopharma Inc. appointed Dr. Sharon Mates to its Board. She joins as a Class I director effective November 3, 2025, with a term through the 2026 annual meeting. The Board deemed her independent under Nasdaq rules. In connection with the appointment, she will receive stock options valued at $450,000, with the number of shares determined by dividing $450,000 by the Common Stock closing price on November 5, 2025. These options vest in full on the earlier of immediately prior to the 2026 annual meeting or the first anniversary of the grant date.
The FDA granted Fast Track Designation to BB-301 for OPMD. The company also announced a live webcast of its latest interim clinical data presentation at 8:00 a.m. Eastern on November 3, 2025. Related press releases and presentation materials were included as exhibits.
Benitec Biopharma Inc. (BNTC) will hold its 2025 Annual Meeting virtually on December 1, 2025 at 1:00 p.m. PT. Stockholders of record at the close of business on October 10, 2025 may vote. As of the record date, 26,250,469 shares of common stock were outstanding. Holders will vote on three items: (1) elect two Class III directors (Dr. Jerel Banks and Megan Boston), (2) ratify Baker Tilly US, LLP as auditor for fiscal year ending June 30, 2026, and (3) approve a non-binding say‑on‑pay advisory vote.
The company will conduct the meeting at www.meetnow.global/M4KC5WC, with voting also available via www.investorvote.com/BNTC. The outstanding count excludes unexercised pre‑funded warrants for up to 15,270,806 shares, which carry no voting rights until exercised. The proxy details quorum and vote standards, committee composition, and director independence. Principal holders include entities affiliated with Suvretta Capital at 49.9%. The proxy also discloses a March 2025 financing with gross proceeds of $30.5 million and net proceeds of $28.2 million, and reports auditor fees of $666,290 for fiscal 2025.